{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:09:29Z","timestamp":1770286169481,"version":"3.49.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T00:00:00Z","timestamp":1390262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Janssen Pharmaceutical K.K."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:p>Because of the potentially high mortality rate (6.5%) associated with bortezomib\u2010induced lung disease (<jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content>) in <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese patients with relapsed or refractory multiple myeloma, we evaluated the incidence, mortality and clinical features of <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content> in a <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese population. This study was conducted under the Risk Minimization Action Plan (<jats:styled-content style=\"fixed-case\">RMAP<\/jats:styled-content>), which was collaboratively developed by the pharmaceutical industry and public health authority. The <jats:styled-content style=\"fixed-case\">RMAP<\/jats:styled-content> consisted of an intensive dissemination of risk information and a recommended countermeasure to health\u2010care professionals. All patients treated with bortezomib were consecutively registered in the study within 1\u00a0year and monitored for emerging <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content>. Of the 1010 patients registered, 45 (4.5%) developed <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content>, 5 (0.50%) of whom had fatal cases. The median time to <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content> onset from the first bortezomib dose was 14.5\u00a0days, and most of the patients responded well to corticosteroid therapy. A retrospective review by the Lung Injury Medical Expert Panel revealed that the types with capillary leak syndrome and hypoxia without infiltrative shadows were uniquely and frequently observed in patients with <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content> compared with those with conditions associated with other molecular\u2010targeted anticancer drugs. The incidence rate of <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apan remains high compared with that reported in other countries, but the incidence and mortality rates are lower than expected before the introduction of bortezomib in <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apan. This study describes the radiographic pattern and clinical characterization of <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content> in the <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese population. The <jats:styled-content style=\"fixed-case\">RMAP<\/jats:styled-content> seemed clinically effective in minimizing the <jats:styled-content style=\"fixed-case\">BILD<\/jats:styled-content> risk among our <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>apanese population.<\/jats:p>","DOI":"10.1111\/cas.12335","type":"journal-article","created":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T12:22:38Z","timestamp":1387023758000},"page":"195-201","source":"Crossref","is-referenced-by-count":26,"title":["Bortezomib therapy\u2010related lung disease in <scp>J<\/scp>apanese patients with multiple myeloma: Incidence, mortality and clinical characterization"],"prefix":"10.1111","volume":"105","author":[{"given":"Kazutake","family":"Yoshizawa","sequence":"first","affiliation":[{"name":"Division of Medical Affairs Janssen Pharmaceutical K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi Y.","family":"Mukai","sequence":"additional","affiliation":[{"name":"Division of Medical Affairs Janssen Pharmaceutical K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Division of Research and Development Janssen Pharmaceutical K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Miyao","sequence":"additional","affiliation":[{"name":"Division of Research and Development Janssen Pharmaceutical K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Research and Development Janssen Pharmaceutical K.K. Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Tokyo Medical University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Katoh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine Department of Internal Medicine Nippon Medical School Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Radiology National Cancer Center Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gemma","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Infectious Disease and Oncology Department of Internal Medicine Nippon Medical School Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumikazu","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Radiology Saitama Medical University International Medical Center Hidaka\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiko","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine Department of Medicine Jichi Medical University Shimotsuke\u2010shi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology Cancer Institute Hospital Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Analytic Human Pathology Nippon Medical School Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kudoh","sequence":"additional","affiliation":[{"name":"Double\u2010Barred Cross Hospital Japan Anti\u2010Tuberculosis Association Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2174\/157489206778776925"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00638.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4541"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06142"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.3307"},{"key":"e_1_2_7_8_1","unstructured":"FDA Guidance for industry development and use of risk minimization action plans March 2005. [Cited 22 Feb 2013.] Available from URL:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071616.pdf."},{"key":"e_1_2_7_9_1","unstructured":"ICH: Harmonization tripartite guideline pharmacovigilance planning E2E November 2004. [Cited 22 Feb 2013.] Available from URL:http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2E\/Step4\/E2E_Guideline.pdf."},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/1874306401206010063"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11532320-000000000-00000"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1720OC"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2235"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.76.4"},{"key":"e_1_2_7_15_1","unstructured":"Pharmaceuticals and Medical Devices Agency Reports on Iressa Tablets 250 prospective study (special investigation). Pharmaceuticals and Medical Devices Agency Safety Information. No. 206 Oct 2004. [Cited 05 Jun 2006.] Available from:http:\/\/www.pmda.go.jp\/english\/service\/pdf\/precautions\/PMDASI-206.pdf."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-4-303"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182598abb"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f1c7b0"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.177.12.1397a"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-012-0438-0"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2012.676110"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0194-0"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.09.015"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2437.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.10.006"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-012-0494-5"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12335","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.12335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.12335","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.12335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T10:33:25Z","timestamp":1694342005000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.12335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,21]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1111\/cas.12335"],"URL":"https:\/\/doi.org\/10.1111\/cas.12335","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,21]]}}}